A drug that blocks the effects of a protein called c-MET tyrosine kinase, which is involved in new blood vessel growth essential for cancer cells to divide and grow. These treatments starve the tumour by stopping the development of a new blood supply (angiogenesis). Doctors call treatments that interfere with the development of a blood supply anti-angiogenic agents. These inhibitors may be used in the treatment of various types of cancers, e.g. cabozantinib (Cabometyx) and savolitinib for renal cell carcinoma.